4a,5,9,10,11,12-hexhydro-1-bromo-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ethylene ketal | 261961-50-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 英文名称: 4a,5,9,10,11,12-hexhydro-1-bromo-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ethylene ketal
• 英文别名: 1-Bromo-4a,5,9,10-tetrahydro-3-methoxy-spiro[6H-benzofuro[3a,3,2-ef][2]benzazepine-6,2'-[1,3]dioxolane]-11(12H)-carboxaldehyde；7'-Bromo-9'-methoxyspiro[1,3-dioxolane-2,14'-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6,8,10(17),15-tetraene]-4'-carbaldehyde
• CAS: 261961-50-6
• 化学式: C₁₉H₂₀BrNO₅
• 分子量: 422.276
• InChiKey: WVNSFKGDKALLKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4a,5,9,10,11,12-hexhydro-1-bromo-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ethylene ketal 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.58h， 以77.9%的产率得到4a,5,9,10,11,12-hexhydro-1-bromo-3-methoxy-11-demethyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ethylene ketal
  参考文献：
  名称：

  Processes for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro-[3a, 3, 2-ef][2]benzazepine

  摘要：

  该发明涉及制备4a,5,9,10,11,12-六氢-6H-苯并呋喃[3a,3,2-ef][2]苯并哌啶或其衍生物的过程。此外，该发明还涉及在制备4a,5,9,10,11,12-六氢-6H-苯并呋喃[3a,3,2-ef][2]苯并哌啶过程中形成的化合物。

  公开号：

  US06369238B1
• 作为产物：
  描述：

  乙二醇 、 N-formyl-1-bromo-narwedine 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以96.7%的产率得到4a,5,9,10,11,12-hexhydro-1-bromo-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ethylene ketal
  参考文献：
  名称：

  Processes for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro-[3a, 3, 2-ef][2]benzazepine

  摘要：

  该发明涉及制备4a,5,9,10,11,12-六氢-6H-苯并呋喃[3a,3,2-ef][2]苯并哌啶或其衍生物的过程。此外，该发明还涉及在制备4a,5,9,10,11,12-六氢-6H-苯并呋喃[3a,3,2-ef][2]苯并哌啶过程中形成的化合物。

  公开号：

  US06369238B1

文献信息

• Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
  申请人：Galantos Pharma GmbH

  公开号：EP1777222A1

  公开（公告）日：2007-04-25

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline of neuronal cholinergic receptors and/or acting as chvlinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. galanthamine, narwedine and lyeoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as "prodrugs", in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the psychiatric diseases vascular dementia, schizophrenia and epilepsy.

  本发明涉及化合物，除了增强神经胆碱能受体对乙酰胆碱和胆碱的敏感性，或者作为胆碱酯酶抑制剂和/或神经保护剂之外，与其原始化合物相比具有增强的血脑屏障渗透性。这些化合物来源于属于石蒜科生物碱类的天然化合物，例如迎春碱、纳尔韦丁和莱奥拉明，或者来源于这些化合物的代谢物（无论是从化学结构上还是直接通过化学合成）。本发明的化合物可以直接与其靶分子相互作用，或者它们可以作为“前药”，意味着在到达体内的靶区域后，它们通过水解或酶攻击转化为原始的母体化合物，并且与其靶分子相互作用，或者两者兼而有之。本发明的化合物可用作治疗与胆碱缺乏相关的人类脑疾病的药物，包括神经退行性疾病阿尔茨海默病和帕金森病，以及精神疾病血管性痴呆、精神分裂症和癫痫。
• CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT
  申请人：Maelicke Alfred

  公开号：US20090253654A1

  公开（公告）日：2009-10-08

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.

  本发明涉及化合物，除了增强神经元胆碱能受体及/或作为胆碱酯酶抑制剂和/或神经保护剂的敏感性，还具有与其母体化合物相比增强的血脑屏障通透性。这些化合物是从天仙子科生物碱类天仙子碱、纳尔韦丁和丝兰碱或其代谢物中衍生出来的（无论是通过其化学结构或直接通过化学合成）。本发明的化合物可以直接与其靶分子相互作用，也可以作为“前药”，在到达体内的目标区域后，通过水解或酶攻击被转化为原始母体化合物，并与其靶分子反应，或两者兼有。本发明的化合物可用作药物。
• Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment
  申请人：Maelicke Alfred

  公开号：US20080261954A1

  公开（公告）日：2008-10-23

  The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g. Galanthamine, narwedine and lycoramine, or from metabolites of said compounds.

  本发明涉及一种化合物，除了增强神经元胆碱能受体及外源性激动剂对乙酰胆碱和胆碱的敏感性，以及作为胆碱酯酶抑制剂和/或神经保护剂外，还具有比其母体化合物更强的血脑屏障通透性。这些化合物是从天仙子科生物碱（例如迎春花碱，纳威丁和莲花碱）或其代谢物中衍生出来的（可以通过其化学结构或直接通过化学合成来实现）。
• US9763953B2
  申请人：——

  公开号：US9763953B2

  公开（公告）日：2017-09-19
• Processes for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro-[3a, 3, 2-ef][2]benzazepine
  申请人：Sanochemia Pharmazeutica

  公开号：US06369238B1

  公开（公告）日：2002-04-09

  The invention relates to processes for the preparation of 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepine, or derivatives thereof. Furthermore, the invention also relates to the compounds formed during the preparation of 4a, 5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepine.

  该发明涉及制备4a,5,9,10,11,12-六氢-6H-苯并呋喃[3a,3,2-ef][2]苯并哌啶或其衍生物的过程。此外，该发明还涉及在制备4a,5,9,10,11,12-六氢-6H-苯并呋喃[3a,3,2-ef][2]苯并哌啶过程中形成的化合物。